Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MyFABT1
NCT02956954Completed
- Sponsor
- Rouen University Hospital
- Start
- Mar 2017
- Primary completion
- Jan 2023
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Open-label trial of agalsidase alfa in Fabry disease (2 arms), sponsored by Rouen University Hospital. Primary endpoint: Difference from baseline in Septal myocardial T1 relaxation time at 24 months. Started Mar 2017; status: completed.
02
Drugs
agalsidase alfa
03
Conditions
Fabry disease
Beyond the preview
Go deeper on NCT02956954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02956954.